Nesiritide Scios

IDrugs

Volumn 5, Issue 7, 2002, Pages 703-709

  Burger, Andrew J ^a   Burger, Mary R ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; GLYCEROL NITRATE; INOTROPIC AGENT; NESIRITIDE; PLACEBO; RECOMBINANT PROTEIN; VASOACTIVE AGENT;

BOLUS INJECTION; BRADYCARDIA; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; COST CONTROL; DISEASE SEVERITY; DOSE RESPONSE; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MARKETING; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EUROPE; FATIGUE; HEART ARREST; HEART ARRHYTHMIA; HEART FAILURE; HEART VENTRICLE TACHYCARDIA; HEMODYNAMIC MONITORING; HOSPITALIZATION; HUMAN; HYPOTENSION; KIDNEY FAILURE; LUNG WEDGE PRESSURE; NONHUMAN; RECOMBINANT DNA TECHNOLOGY; REST; REVIEW; STRUCTURE ACTIVITY RELATION; TOXICITY TESTING; UNITED STATES; VASODILATATION;

EID: 0141508031     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. 241190 Acute effects of physiological increments of brain natriuretic peptide in humans. La Villa G, Stefani L, Lazzeri C, Zurli C, Guerra CT, Barletta G, Bandinelli R, Strazulla G, Franchi F Hypertension 1995 26 4 628-633 Effects of incremental BNP infusions in healthy men.
2. 287046 Scios holds annual meeting. Scios Inc Press Release 1998 May 12
3. 287943 Bayer and Scios announce worldwide strategic alliance for Natrecor in congestive heart failure/First new drug for short-term treatment of HCF in a decade. Bayer AG Press Release 1998 May 26
4. 294105 Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. Abraham WT, Lowes BD, Ferguson DA, Odom J, Kim JK, Robertson AD, Bristow MR, Schrier RW J Cardiac Failure 1998 4 1 37-44 Effects of a continuous 4-h infusion of BNP in decompensated failure patients.
5. 294107 Human brain natriuretic peptide reduces blood pressure in normotensive and acute norepinephrine-induced hypertensive rabbits. Clemens LE, Almirez RG, Baudouin KA, Grossbard EB, Protter AA Am J Hypertens 1997 10 6 654-661 This study established that rabbits are a useful model in which to study the effects of hBNP and can thus be subsequently used as an experimental model of natriuretic peptide action.
6. 301433 Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. Holmes SJ, Espiner EA, Richards AM, Yandle TG, Frampton C J Clin Endocrinol Metab 1993 76 1 91-96 Effect of 2-h infusions of BNP in healthy men.
7. 312977 FDA Advisory Committee recommends approval of Natrecor for the short-term management of congestive heart failure. Scios Inc Press Release 1999 January 29
8. 314716 Natrecor phase IV study should assess drug in acute MI, cmte says. FDC Reports Pink Sheet 1999 61 5 5
9. 315686 Life Sciences Germany: Bayer. Lehman Brothers Inc 1998 October 19
10. 319225 Healthcare global: PharmaPipelines - Volume 1 of 2. Lehman Brothers Inc 1999 February
11. 322857 Natrecor NDA not approved by FDA. Scios Inc Press Release 1999 April 27
12. 324200 Scios discusses next steps for Natrecor with FDA. Scios Inc Press Release 1999 May 11
13. 327424 Scios and Bayer dissolve commercial alliance regarding Natrecor in acute congestive heart failure. Scios Inc Press Release 1999 June 09
14. 331503 Therapeutic potential of nesiritide (recombinant B-type natriuretic peptide) in the treatment of heart failure. Hobbs RE, Mills RM Expert Opin Investig Drugs 1998 8 7 1063-072 Review of nesiritide in the treatment of heart failure.
15. 241213 Sustained hemodynamic effects of an infusion of nesiritide (human B-type natriuretic peptide) in heart failure: A randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group. Mills RM, LeJemtel TH, Horton DP, Liang C, Lang R, Silver MA, Lui C, Chatterjee K Am Coll Cardiol 1999 34 1 155-162
16. 395732 Scios files amendment to Natrecor new drug application with US Food and Drug Administration - Company to present at Chase H&Q Investor Conference tomorrow. Scios Inc Press Release 2001 January 10
17. 402363 Scios begins enrollment in Natrecor pharmacoeconomic study. Scios Inc Press Release 2001 March 19
18. 410865 Scios announces FDA Advisory Committee unanimously recommends approval of Natrecor for acute congestive heart failure. Scios Inc Press Release 2001 May 25
19. 415073 Scios receives Natrecor approvable letter. Scios Inc Press Release 2001 July 10
20. 416234 Scios completes pre-approval inspection for Natrecor. Scios Inc Press Release 2001 July 19
21. 418946 Scios announces FDA Approval of Natrecor; Company prepared to launch in US hospitals by end of August. Scios Inc Press Release 2001 August 13
22. 420072 Scios launches Natrecor in United States. Scios Inc Press Release 2001 August 22
23. 427021 Scios reports third quarter 2001 financial results. Scios Inc Press Release 2001 October 25
24. 435015 Scios and GlaxoSmithKline sign licensing agreement for Natrecor in Europe. Scios Inc Press Release 2002 January 07
25. 443975 Effects on nesiritide (B-type natriuretic peptide) in decompensated heart failure patients receiving β-blockers. Abraham WT Circulation 2001 104 17 Abs 2000 VMAC trial. Comparison of patients on or off β-blocker therapy when treated with nesiritide compared to nitroglycerin.
26. 444959 Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure. Publication Committee for the VMAC Investigators J Am Med Assoc 2002 287 12 1531-1540 VMAC trial results. Comparison of nitroglycerin and nesiritide for the treatment of acutely decompensated heart failure patients.
27. 446478 Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. Silver MA, Horton DP, Ghali JK, Elkayam U J Am Coll Cardiol 2002 39 5 798-803 Outcomes of decompensated heart failure patients treated with dobutamine compared to nesiritide.
28. 446490 An update on nesiritide for treatment of decompensated heart failure. Hobbs RE, Mills RM, Young JB Hosp Pharm 2001 36 12 1278-1289
29. 446551 Comparison of the occurrence of ventricular arrhythmias in patients with acutely decompensated congestive heart failure receiving dobutamine versus nesiritide therapy. Burger AJ, Elkayam U, Neibaur MT, Haught H, Ghali J, Horton DP, Aronso D Am J Cardiol 2001 88 1 35-39 Comparison of the arrhythmias generated by treatment of decompensated heart failure with dobutamine versus nesiritide.
30. 446555 Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Colucci WS, Elkayam U, Horton DP, Abraham WT, Bourge RC, Johnson AD, Wagoner LE, Givertz MM, Liang CS, Neibaur M, Haught WH, Lejemtel TH N Engl J Med 2000 343 4 246-253 Summary of two multicenter phase III trials of nesiritide inn decompensated heart failure patients.
31. 446957 Research & development: Product pipeline. GlaxoSmithKlinne plc Company World Wide Web Site 2002 March 28
32. 448665 Scios announces first quarter results and increases 2002 Natrecor sales forecast. Scios Inc Press Release (2002) April 18
33. 456148 BNP in decompensated heart failure: Diagnostic, prognostic and therapeutic potential. Burger MR, Burger AJ Curr Opin Invest Drugs 2001 2 7 929-935
34. 456342 Natrecor (nesiritide). Scios Inc Company World Wide Web Site 2002 June 26 Full prescribing information on nesiritide.
35. 456345 The neurohumoral axis in congestive heart failure. Francis GS, Goldsmith SR, Levine TB, Olivari MT, Cohn JN Ann Intern Med 1984 101 3 370-377
36. 456346 Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, Ohnishi M, Sawaki M, Fujii M, Matsumoto T, Matsui T, Kinoshita M J Am Coll Cardiol 2001 37 5 1228-1233
37. 456349 The natriuretic peptides in heart failure: Diagnostic and therapeutic potentials. Chen HH, Burnett JC Jr Proc Association Am Physicians 1999 111 5 406-416
38. 456352 Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Yoshimura M, Yasue H, Morita E, Sakaino N, Jougasaki M, Kurose M, Mukoyama M, Saito Y, Nakao K, Imura H Circulation 1991 84 4 1581-1588 Effects of BNP infusion on multiple physiological parameters in CHF patients.
39. 456354 Effects of brain (B-type) natriuretic peptide on coronary artery diameter and coronary hemodynamic variables in humans: Comparison with effects on systemic hemodynamic variables. Okumura K, Yasue H, Fujii H, Kugiyama K, Matsuyama K, Yoshimura M, Jougasaki M, Kikuta K, Kato H, Tanaka H et al. J Am Coll Cardiol 1995 25 2 342-348
40. 456355 Hemodynamic effects of a single intravenous injection of synthetic human brain natriuretic peptide in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Hobbs RE, Miller LW, Bott Silverman C, James KB, Rincon G, Grossbard EB Am J Cardiol 1996 78 8 896-901 Effects of a single intravenous bolus of nesiritide in heart failure patients (phase II study).
41. 456359 Differing biological effects of equimolar atrial and brain natriuretic peptide infusions in normal man. Hunt PJ, Espiner EA, Nicholls MG, Richards AM, Yandle TG J Clin Endocrinol Metab 1996 81 11 3871-3876 Comparison of the effects of ANP and BNP infusions in healthy men.
42. 456361 Renal, endocrine, and hemodynamic interactions of atrial and brain natriuretic peptides in normal men. Florkowski CM, Richards AM, Espiner EA, Yandle TG, Frampton C Am J Physiol 1994 266 4 Pt 2 R1244-R1250 Effect of BNP infusion added to ANP infusions in healthy men.
43. 456363 Vascular actions of brain natriuretic peptide: Modulation by atherosclerosis and neutral endopeptidase inhibition. Schirger JA, Grantham JA, Kullo IJ, Jougasaki M, Wennberg PW, Chen HH, Lisy O, Miller V, Simari RD, Burnett JC Jr J Am Coll Cardiol 2000 35 3 796-801 Effect of BNP on cellular proliferation in human vascular smooth muscle cells.
44. 456364 Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, Jougasaki M, Ogawa H, Okumura K, Mukoyama M, Nakao K Circulation 1994 90 1 195-203 Secretion of BNP localized to the left ventricle in proportion to the degree of heart failure
45. 456366 Sustained symptom improvement with nesiritide (B-type natriuretic peptide) compared to IV nitroglycerin in patients with acute decompensated heart failure. Young JB, VMAC Study Group J Cardiac Failure 2001 7 Suppl 2 12 VMAC trial. Symptom improvement in heart failure patients treated with nesiritide compared to nitroglycerin.
46. 458882 Effect of BNP on renal hemodynamics, tubular function and vasoactive hormones in humans. Jensen KT, Carstens J, Pederson EB Am J Physiol 1998 274 1 Pt 2 F63-F72 Effect of BNP infusion on renal parameters in healthy men.
47. 459827 The effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: The PRECEDENT study. Burger AJ, Horton DP, LeJemtel T, Ghali JK, Torre G, Dennish G, Koren M, Dinerman J, Silver M, Cheng ML, Elkayam U Am Heart J 2002 143 In press